Cargando…
Blood Pressure Control in Patients with Diabetic Kidney Disease
Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease. Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested...
Autores principales: | Kim, Yaeni, Kim, Won, Kim, Jwa-Kyung, Moon, Ju Young, Park, Samel, Park, Cheol Whee, Park, Hoon Suk, Song, Sang Heon, Yoo, Tae-Hyun, Lee, So-Young, Lee, Eun Young, Lee, Jeonghwan, Jin, Kyubok, Cha, Dae Ryong, Cha, Jin Joo, Han, Sang Youb |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Electrolyte Metabolism
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827046/ https://www.ncbi.nlm.nih.gov/pubmed/36688208 http://dx.doi.org/10.5049/EBP.2022.20.2.39 |
Ejemplares similares
-
Upregulation of VSIG4 in Type 2 Diabetic Kidney Disease
por: Han, Sang Youb, et al.
Publicado: (2022) -
The Role of V-Set Ig Domain-Containing 4 in Chronic Kidney Disease Models
por: Han, Sang Youb, et al.
Publicado: (2023) -
New therapeutic agents in diabetic nephropathy
por: Kim, Yaeni, et al.
Publicado: (2017) -
Adenosine monophosphate–activated protein kinase in diabetic nephropathy
por: Kim, Yaeni, et al.
Publicado: (2016) -
Response to comment on “New therapeutic agents in diabetic nephropathy”
por: Kim, Yaeni, et al.
Publicado: (2017)